MedTrace Logo

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)

NCT02332499 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 419

Last updated 2019-05-21

No results posted yet for this study

Summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.

Conditions

Interventions

DRUG

Anlotinib

Anlotinib p.o. qd

DRUG

Placebo

Placebo p.o. qd

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yihebali Chi, doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Jianqiang Cai, doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Jinwan Wang, doctor · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-08-18
Completion
2019-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02332499 on ClinicalTrials.gov